Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...

H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $5.50 per share a year ago. These ...

Reports Q4 revenue $629k, consensus $433.33k. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated ...

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...

Rostermania rages on in North America with many of Apex's biggest names finding themselves new homes. With year five of the ...

ALIGOS THERAPEUTICS ($ALGS) is expected to release its quarterly earnings data on Monday, March 10th before market open, per Finnhub. Analysts are expecting revenue ...

With the Year 4 Championship ending, Respawn Entertainment has revealed its plans for the upcoming ALGS Year 5 tournament. The developer said it will be introducing a big LAN event open to 160 teams.

R&D expenses for the year ended December 31, 2024 were $70.3 million, compared with $73.0 million for the same period of 2023. Total R&D employee-related costs reduced by $4.2 million which was ...

Beam Therapeutics Begins Dosing in Phase I/II AATD Study Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational ...

Esports athlete Reps to leave TSM after nearly six years of professional play with the team, but shares that he's not quitting Apex Legends.